Journal Watch · Frontiers in Immunology · 2026
Immunogenetic modulation of endothelial inflammation by the LIPG -384A/C promoter variant influences COVID-19 severity.
Our findings underscore the critical role of host immunogenetic factors at the immune-endothelial interface in shaping inflammatory responses and clinical outcomes in COVID-19, providing insight into vascular immunopathology and host susceptibility.
TL;DR
Our findings underscore the critical role of host immunogenetic factors at the immune-endothelial interface in shaping inflammatory responses and clinical outcomes in COVID-19, providing insight into vascular immunopathology and host susceptibility.
Key findings
- Computational functional annotation revealed that the -384A/C substitution modifies transcription factor binding motifs linked to inflammatory and immune-responsive pathways, supporting a mechanistic role for this variant in regulating endothelial immune signaling.<h4>Conclusion</h4>This study identifies the <i>LIPG</i> -384A/C promoter variant as a novel immunogenetic determinant of COVID-19 severity, potentially mediating disease progression through modulation of immune-driven endothelial inflammation.
- Our findings underscore the critical role of host immunogenetic factors at the immune-endothelial interface in shaping inflammatory responses and clinical outcomes in COVID-19, providing insight into vascular immunopathology and host susceptibility.
What they did
Genotyping of the <i>LIPG</i> -384A/C (rs3813082) promoter variant was carried out using polymerase chain reaction-based allelic discrimination. Associations between genotype and disease severity were evaluated alongside inflammatory and immune-related parameters, including serum ferritin and total leukocyte count. <i>In silico</i> analyses were conducted to assess the impact of the promoter variant on transcription factor binding sites involved in immune and inflammatory regulation.<h4>Results</h4>The <i>LIPG</i> -384C allele was significantly associated with an increased risk of severe COVID-19 and a heightened inflammatory profile. Individuals carrying the risk allele demonstrated significantly elevated ferritin levels and leukocyte counts, indicative of amplified systemic immune activation.
Full abstract (original)
Background: <h4>Background</h4>Severe COVID-19 is characterized by dysregulated host immune responses and immune-mediated endothelial injury, culminating in microvascular dysfunction and systemic inflammation. Endothelial lipase (EL), encoded by the <i>LIPG</i> gene, regulates endothelial lipid metabolism and inflammatory signaling pathways that influence immune-endothelial interactions. Despite its relevance to vascular immunopathology, the immunogenetic contribution of <i>LIPG</i> promoter variants to immune-driven endothelial dysfunction in COVID-19 remains poorly defined.<h4>Methods</h4>We performed a case-control study including 151 RT-PCR-confirmed COVID-19 patients stratified according to disease severity and 152 healthy controls.
What they did: Genotyping of the <i>LIPG</i> -384A/C (rs3813082) promoter variant was carried out using polymerase chain reaction-based allelic discrimination. Associations between genotype and disease severity were evaluated alongside inflammatory and immune-related parameters, including serum ferritin and total leukocyte count. <i>In silico</i> analyses were conducted to assess the impact of the promoter variant on transcription factor binding sites involved in immune and inflammatory regulation.<h4>Results</h4>The <i>LIPG</i> -384C allele was significantly associated with an increased risk of severe COVID-19 and a heightened inflammatory profile. Individuals carrying the risk allele demonstrated significantly elevated ferritin levels and leukocyte counts, indicative of amplified systemic immune activation.
Results & conclusions: Computational functional annotation revealed that the -384A/C substitution modifies transcription factor binding motifs linked to inflammatory and immune-responsive pathways, supporting a mechanistic role for this variant in regulating endothelial immune signaling.<h4>Conclusion</h4>This study identifies the <i>LIPG</i> -384A/C promoter variant as a novel immunogenetic determinant of COVID-19 severity, potentially mediating disease progression through modulation of immune-driven endothelial inflammation. Our findings underscore the critical role of host immunogenetic factors at the immune-endothelial interface in shaping inflammatory responses and clinical outcomes in COVID-19, providing insight into vascular immunopathology and host susceptibility.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1785738 · PubMed 42317324.
Why it matters for pharma & biotech
- Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Frontiers in Immunology study find?
Our findings underscore the critical role of host immunogenetic factors at the immune-endothelial interface in shaping inflammatory responses and clinical outcomes in COVID-19, providing insight into vascular immunopathology and host susceptibility.
What type of study is this?
It is a clinical study, published in Frontiers in Immunology in 2026. Genotyping of the <i>LIPG</i> -384A/C (rs3813082) promoter variant was carried out using polymerase chain reaction-based allelic discrimination.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1785738. PubMed ID: 42317324. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/immunogenetic-modulation-of-endothelial-inflammation-by-the-lipg-384a-c-785738/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides